- Details
- Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The conversation...
|
- Details
- Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents. He explains how these characteristics allow for next-day imaging, potentially improving detection rates and clinical flexibility. Dr. Shor...
|
- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate. The COBRA trial reveals that imaging performed the...
|
- Details
- Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. He notes that while ligands like Gallium PSMA-11 and DCFPyL are similar and FDA-approved, others like PSMA-1007, although widely used...
|
- Details
- Phillip Koo and Neal Shore discuss the COBRA trial, which investigates the use of 64Cu-SAR-bisPSMA PET imaging in prostate cancer patients with biochemical recurrence (BCR). Dr. Shore, the lead principal investigator, introduces Clarity, an Australian company developing Copper-64-based radiopharmaceuticals. He explains the advantages of Copper-64, such as its long half-life and bivalent structure,...
|
- Details
- Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions. It categorizes patients based on PET scan results: those without detectable cancer outside the pelvis...
|
- Details
- Phillip Koo converses with Faina Shtern who highlights that this year's Summit aims to bridge the significant gaps between the imaging community and clinical community. She emphasizes the future of prostate cancer diagnosis and treatment lies in the integration of multiple diagnostic methods such as MRI, molecular imaging, and genomic profiling. The 2023 Summit will introduce a multiomics panel fo...
|
- Details
- Phillip Koo talks with Jeremie Calais about the EMBARK trial and the impact of PSMA PET on patient population characterization. The discussion explores how the EMBARK trial began back in 2015 before the existence of PSMA PET and how its introduction has affected the understanding and definition of patient populations in prostate cancer studies. Calais explains how their team retrospectively looked...
|
- Details
- Philip Koo discusses the newly updated PSMA PET/CT: Joint EANM, SNMMI procedure guideline, version 2.0, with its first and senior authors, Wolfgang Fendler and Ken Herrmann from Germany. The updated guideline, considered a landmark paper, integrates new ligands and types of imaging, consolidating information on PSMA imaging for different ligands and formalizing them as a class of ligands. It featu...
|
